CoChat

Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma

Open access
Yeung, Choh, Gibson, Anna E., Issaq, Sameer H., Oshima, Nobu, Baumgart, Joshua T., Edessa, Leah D., Rai, Ganesha, Urban, Daniel J., Johnson, Michelle S., Benavides, Gloria A., Squadrito, Giuseppe L., Yohe, Marielle E., Lei, Haiyan, Eldridge, Sandy, Hamre, John, Dowdy, Tyrone, Ruiz-Rodado, Victor, Lita, Adrian, Mendoza, Arnulfo, Shern, Jack F., Larion, Mioara, Helman, Lee J., Stott, Gordon M., Krishna, Murali C., Hall, Matthew D., Darley-Usmar, Victor, Neckers, Leonard M., Heske, Christine M. · 2019 · Cancer Research
Cited by 131

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Altered cellular metabolism, including an increased dependence on aerobic glycolysis, is a hallmark of cancer. Despite the fact that this observation was first made nearly a century ago, effective therapeutic targeting of glycolysis in cancer has remained elusive. One potentially promising approach involves targeting the glycolytic enzyme lactate dehydrogenase (LDH), which is overexpressed and plays a critical role in several cancers. Here, we used a novel class of LDH inhibitors to demonstrate, for the first time, that Ewing sarcoma cells are exquisitely sensitive to inhibition of LDH. EWS-FLI1, the oncogenic driver of Ewing sarcoma, regulated LDH A (LDHA) expression. Genetic depletion of LDHA inhibited proliferation of Ewing sarcoma cells and induced apoptosis, phenocopying pharmacologic inhibition of LDH. LDH inhibitors affected Ewing sarcoma cell viability both in vitro and in vivo by reducing glycolysis. Intravenous administration of LDH inhibitors resulted in the greatest intratumoral drug accumulation, inducing tumor cell death and reducing tumor growth. The major dose-limiting toxicity observed was hemolysis, indicating that a narrow therapeutic window exists for these compounds. Taken together, these data suggest that targeting glycolysis through inhibition of LDH should be further investigated as a potential therapeutic approach for cancers such as Ewing sarcoma that exhibit oncogene-dependent expression of LDH and increased glycolysis. Significance: LDHA is a pharmacologically tractable EWS-FLI1 transcriptional target that regulates the glycolytic dependence of Ewing sarcoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-19-0217

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 131

Metadata

Authors
Yeung, C., Gibson, A. E., Issaq, S. H., Oshima, N., Baumgart, J. T., Edessa, L. D., Rai, G., Urban, D. J., Johnson, M. S., Benavides, G. A., Squadrito, G. L., Yohe, M. E., Lei, H., Eldridge, S., Hamre, J., Dowdy, T., Ruiz-Rodado, V., Lita, A., Mendoza, A., Shern, J. F., Larion, M., Helman, L. J., Stott, G. M., Krishna, M. C., Hall, M. D., Darley-Usmar, V., Neckers, L. M., & Heske, C. M.
Venue
Cancer Research
Published
2019-10-01
Volume
79
Issue
19
Pages
5060-5073
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2969950932
Cited by
131
References
7
FWCI
4.98
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-19-0217
The paper
Yeung, C., Gibson, A. E., Issaq, S. H., Oshima, N., Baumgart, J. T., Edessa, L. D., Rai, G., Urban, D. J., Johnson, M. S., Benavides, G. A., Squadrito, G. L., Yohe, M. E., Lei, H., Eldridge, S., Hamre, J., Dowdy, T., Ruiz-Rodado, V., Lita, A., Mendoza, A., . . . Heske, C. M. (2019). Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-19-0217

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.